Chondrosarcoma Diagnosis and Treatment Strategies

Chondrosarcoma is a primary malignant bone tumour arising from cartilaginous cells and represents the second most common bone sarcoma worldwide. Diagnosis combines clinical assessment with advanced imaging modalities—magnetic resonance imaging to evaluate marrow and soft-tissue involvement, computed tomography for matrix calcification, and positron emission tomography for metabolic activity—followed by histopathological grading to distinguish low-grade lesions from high-grade and dedifferentiated subtypes. Conventional chondrosarcomas often resist chemotherapy and radiotherapy, rendering surgical resection with clear margins the principal curative approach. Margin status, tumour location—particularly pelvic sites—and histological grade are established prognostic factors. Recent advances in molecular profiling have revealed recurrent IDH mutations, epigenetic dysregulation and microRNA signatures that underpin malignant behaviour. These findings are informing the development of targeted therapies, including inhibitors of mutant IDH enzymes, angiogenesis blockers and novel agents modulating tumour microenvironment. A multidisciplinary strategy involving orthopaedic oncology, radiology and pathology is essential to optimise outcomes and to integrate emerging systemic treatments in clinical practice.

Research from Nature Portfolio

Recent studies employing single-cell transcriptomics have constructed a detailed atlas of conventional central chondrosarcoma, uncovering that reduced endoplasmic reticulum stress promotes tumour proliferation, while excessive stress induces apoptosis. Key regulators such as DNA Damage Inducible Transcript 3 emerge as candidate markers for malignant transformation, and modulation of the NF-κB pathway offers a potential avenue to enhance cell death in refractory tumours. Complementary multi-omics analyses have defined two molecular subtypes of chondrosarcoma according to tumour differentiation and cell-cycle activation. Integration of mRNA, microRNA and DNA methylation profiles has led to a streamlined mRNA-only classifier capable of predicting patient outcome and tracking disease progression through relapse, thus paving the way for molecularly guided risk stratification and personalised interventions.

Chondrosarcoma Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in chondrosarcoma diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Histopathological grading: A system that categorises tumours by cellular atypia and mitotic activity to predict aggressiveness and guide treatment.

Endoplasmic reticulum (ER) stress: A cellular condition in which accumulation of unfolded proteins triggers adaptive or apoptotic pathways, influencing tumour survival.

NF-κB pathway: A signalling cascade that regulates genes involved in inflammation, cell proliferation and survival, often co-opted by cancer cells to resist stress.

Multi-omics: An integrative analytical approach combining genomic, transcriptomic, epigenomic and proteomic data to characterise disease subtypes.

mRNA-only classifier: A prognostic tool that uses expression levels of a defined set of messenger RNAs to assign risk categories without requiring full multi-omics profiling.

References

1. A single-cell atlas of conventional central chondrosarcoma reveals the role of endoplasmic reticulum stress in malignant transformation. Communications Biology (2024).
2. Chondrosarcoma: biology, genetics, and epigenetics. F1000Research (2018).
3. The Identification of Prognostic Factors and Survival Statistics of Conventional Central Chondrosarcoma. Sarcoma (2015).
4. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nature Communications (2019).
5. Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers (2021).